Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study

Fig. 3

Longitudinal 6-months interval change during pirfenidone treatment in a) FVC % of predicted (ΔFVC); b) TLCO % of predicted (ΔTLCO). Data are presented as median (IQR) values. Notes: *p < 0.05, **p < 0.01. Abbreviations: FVC – forced vital capacity, TLCO – transfer factor of the lung for carbon monoxide

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us